An early Phase 2A study of patients with moderate-to-severe asthma with 300 eosinophils/μL or a sputum eosinophil level greater than 3% reported that dupilumab significantly reduced exacerbations, serum IgE, eotaxin-3, TARC, and the biomarker FeNO, with significant increases from baseline in FEV1 seen at week 2, which continued through to week 12, although patients had been instructed to taper and stop inhaled glucocorticoids during weeks 6 to 9 [102]. This evidence concerns the gene IGHE and asthma.